ACU193, a Monoclonal Antibody that Selectively Binds Soluble Aß Oligomers: Development Rationale, Phase 1 Trial Design, and Clinical Development Plan.
- DOI
- 10.14283/jpad.2022.93
- Published
- 2023
- Container
- The journal of prevention of Alzheimer's disease
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.14283/jpad.2022.93,
title = {ACU193, a Monoclonal Antibody that Selectively Binds Soluble Aß Oligomers: Development Rationale, Phase 1 Trial Design, and Clinical Development Plan.},
author = {Siemers E and Hitchcock J and Sundell K and Dean R and Jerecic J and Cline E and Iverson K and Moore J and Edgar C and Manber R and Fuin N and Poppe T and Barton R},
year = {2023},
journal = {The journal of prevention of Alzheimer's disease},
doi = {10.14283/jpad.2022.93},
url = {https://doi.org/10.14283/jpad.2022.93}
}RIS
TY - JOUR TI - ACU193, a Monoclonal Antibody that Selectively Binds Soluble Aß Oligomers: Development Rationale, Phase 1 Trial Design, and Clinical Development Plan. AU - Siemers E AU - Hitchcock J AU - Sundell K AU - Dean R AU - Jerecic J AU - Cline E AU - Iverson K AU - Moore J AU - Edgar C AU - Manber R AU - Fuin N AU - Poppe T AU - Barton R PY - 2023 JO - The journal of prevention of Alzheimer's disease DO - 10.14283/jpad.2022.93 UR - https://doi.org/10.14283/jpad.2022.93 ER -
APA
E, S., J, H., K, S., R, D., J, J., E, C., K, I., J, M., C, E., R, M., N, F., T, P., & R, B. (2023). ACU193, a Monoclonal Antibody that Selectively Binds Soluble Aß Oligomers: Development Rationale, Phase 1 Trial Design, and Clinical Development Plan.. The journal of prevention of Alzheimer's disease. https://doi.org/10.14283/jpad.2022.93
Source records
- pubmed · retrieved 2026-09-27T01:21:44.991Z